ClinicalTrials.gg
RecruitingNCT07542652Updated Apr 30, 2026

Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis

An observational study in Gastric Carcinoma, Gastritis Chronic and Intestinal Metaplasia, sponsored by Yongquan Shi. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Yongquan Shi · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
450
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this clinical trial is to explore the correlation between the level of microplastic exposure and the risk of gastric mucosal carcinogenesis, and to evaluate the strength of its effect as an independent risk factor. The main questions it aims to answer include: Does the level of microplastic exposure increase the risk of gastric mucosal carcinogenesis? Can the correlation between the level of microplastic exposure and gastric mucosal carcinogenesis, as well as the sources of high - risk microplastic exposure, be explored through a questionnaire on external microplastic exposure? Researchers will complete a design structured questionnaire and ask participants to fill it out carefully and truthfully to determine whether the level of microplastic exposure increases the risk of gastric mucosal carcinogenesis.

Read the detailed description

The study will categorize participants into three groups based on endoscopic and/or histopathological findings: chronic non-atrophic gastritis, precancerous lesions, and gastric cancer. Basic demographic information, *Helicobacter pylori* infection status, and plastic exposure assessment scores will be recorded for each group.

02

Conditions studied

  • Gastric Carcinoma
  • Gastritis Chronic
  • Intestinal Metaplasia
  • Gastric Precancerous Lesions

Browse trials for

03

In context

Stomach Neoplasms

3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.

This study's planned enrollment of 450 is above the median of 278 across 790 observational studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Yongquan Shi is the lead sponsor of 9 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients were enrolled from a single center, Xijing Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75 years old, gender is not restricted
  • Having a clear diagnosis result within the recent three months and being diagnosed with chronic non - atrophic gastritis, precancerous lesions of gastric cancer, or gastric cancer for the first time
  • Have clear Helicobacter pylori (Hp) test results
  • Be in normal mental state and able to independently complete the questionnaire survey

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of malignant tumors in other parts
  • Patients who have previously undergone upper gastrointestinal surgery, chemotherapy, or radiotherapy
  • Patients with severe diseases of major organs such as the heart, lungs liver, and kidneys
  • Patients who are currently receiving psychological intervention or taking psychiatric drugs
  • Pregnant or lactating women
  • Patients with severe missing clinical data or questionnaire information
  • Refusing to sign the form
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • Chronic non-atrophic gastritis

    Patients diagnosed with chronic non-atrophic gastritis based on endoscopic and/or histopathological results

  • precancerous lesion

    Patients with chronic atrophic gastritis, gastric intestinal metaplasia, and gastric intraepithelial neoplasia based on endoscopic and/or histopathological results

  • gastric cancer

    patients with gastric cancer according to endoscopic and/or histopathological results

06

What researchers measure

Primary outcomes

  1. Correlation between external exposure levels of microplastics and three pathological stages of gastric mucosal carcinogenesis

    The investigators evaluated the correlation between external exposure to microplastics and the three pathological stages of gastric mucosal carcinogenesis based on the patients' final diagnosis results and the completed questionnaires they filled out.

    Time frame: 9 months

Secondary outcomes

  1. Analysis of sources of high - risk microplastic exposure

    Analyze the sources of high-risk microplastic exposure by comparing the scores of each item in the questionnaires of the three groups of participants.

    Time frame: 9 months

  2. Synergistic toxicity of microplastics and Helicobacter pylori

    Analyze whether microplastics synergistically promote gastric mucosal injury and increase the risk of canceration with Helicobacter pylori through interaction.

    Time frame: 9 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07542652
Lead sponsor
Yongquan Shi
Responsible party
Yongquan Shi (Professor, Xijing Hospital of Digestive Diseases) — Sponsor-investigator
First posted
Apr 21, 2026
Start date
Mar 31, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 30, 2026

Study contacts

Yongquan Shi
Contact
shiyquan@fmmu.edu.cn
029-84771515

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion